from the NIH. The author thanks Soren Hansen for helpful suggestions.

1. Wu, H., et al. 2003. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. *J. Clin. Invest.* **111**:1589–1602. doi:10.1172/JCI200316889.
2. Goerke, J. 1998. Pulmonary surfactant: functions and molecular composition. *Biochim. Biophys. Acta.* **1408**:79–89.
3. Whitsett, J.A., Nogue, L.M., Weaver, T.E., and Horowitz, A.D. 1995. Human surfactant protein B: structure, function, regulation, and genetic disease. *Physiol. Rev.* **75**:749–757.
4. Wright, J.R. 1997. Immunomodulatory functions of surfactant. *Physiol. Rev.* **77**:931–962.
5. Crouch, E., and Wright, J.R. 2001. Surfactant proteins A and D and pulmonary host defense. *Annu.*

- Rev. Physiol.* **63**:521–554.
6. Crouch, E., Hartshorn, K., and Ofek, I. 2000. Collectins and pulmonary innate immunity. *Immunol. Rev.* **173**:52–65.
7. Weis, W.I., and Drickamer, K. 1994. Trimeric structure of a C-type mannose-binding protein. *Structure.* **2**:1227–1240.
8. Crouch, E.C. 1998. Collectins and pulmonary host defense. *Am. J. Respir. Cell Mol. Biol.* **19**:177–201.
9. Lawson, P.R., and Reid, K.B. 2000. The roles of surfactant proteins A and D in innate immunity. *Immunol. Rev.* **173**:66–78.
10. Jack, D.L., Klein, N.J., and Turner, M.W. 2001. Mannose-binding lectin: targeting the microbial world for complement attack and opsonophagocytosis. *Immunol. Rev.* **180**:86–99.
11. Jacobs, H., et al. 1982. Premature lambs rescued from respiratory failure with natural surfactant:

- clinical and biophysical correlates. *Pediatr. Res.* **16**:424–429.
12. Griesse, M. 1999. Pulmonary surfactant in health and human lung diseases: state of the art. *Eur. Respir. J.* **13**:1455–1476.
13. Gunther, A., et al. 2001. Surfactant alteration and replacement in acute respiratory distress syndrome. *Respir. Res.* **2**:353–364.
14. Jobe, A.H. 2000. Which surfactant for treatment of respiratory-distress syndrome. *Lancet.* **355**:1380–1381.
15. Madsen, J., et al. 2000. Localization of lung surfactant protein D on mucosal surfaces in human tissue. *J. Immunol.* **164**:5866–5870.
16. Akiyama, J., et al. 2002. Tissue distribution of surfactant proteins A and D in the mouse. *J. Histochem. Cytochem.* **50**:993–996.
17. Dutton, J.M., et al. 1999. Surfactant protein A in rabbit sinus and middle ear mucosa. *Ann. Otol. Rhinol. Laryngol.* **108**:915–924.

See the related article beginning on page 1547.

The mitochondriotoxic domain of Vpr determines HIV-1 virulence

Catherine Brenner¹ and Guido Kroemer²

¹Centre National de la Recherche Scientifique, Formation de Recherche en Évolution 2445, Université de Versailles/St. Quentin, Versailles, France

²Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8125, Institut Gustave Roussy, Villejuif, France

J. Clin. Invest. **111**:1455–1457 (2003). doi:10.1172/JCI200318609.

Most patients infected with HIV-1 develop AIDS unless they receive antiretroviral medication. However, a small number of HIV-infected individuals with high viral titers remain disease free and do not experience progressive immunosuppression, even in the absence of therapy. Such individuals are labeled long-term nonprogressors (LTNPs) and are characterized by a series of laboratory parameters that are usually compromised in HIV-1 carriers who ultimately develop AIDS. In particular, LTNPs possess a high frequency of peripheral CD4⁺

T cells, as well as a low level of spontaneous apoptosis, correlating with a normal mitochondrial transmembrane potential ($\Delta\psi_m$) among circulating T cells. It has long been assumed that, as an *experimentum naturae*, LTNPs might furnish valuable clues for the identification of molecular determinants of HIV-1 pathogenesis. A study by Badley and colleagues involving LTNPs, reported in this issue of the *JCI* (1), strongly suggests that viral protein R (Vpr) is a major HIV-1 virulence factor.

Vpr – a cytotoxic protein encoded by HIV-1

The HIV-1 genome encodes structural and enzymatic proteins common to all retroviruses, but also some accessory proteins that are not always required for the replication of HIV-1. One of these accessory proteins, Vpr, is found in virions, HIV-1-infected cells, and in the serum and cerebrospinal fluid of HIV-1 carriers. Vpr is a small (96 amino acids) soluble protein composed of three α -helical domains (Figure 1a). Vpr is dispensable for viral replication

in T lymphocytes, but not in monocytes, and thus is rapidly lost among laboratory HIV-1 isolates. In contrast, Vpr is maintained in most HIV-1-infected patients, indicating that this protein may be important for the *in vivo* biology of HIV-1. *In vitro*, Vpr reduces the proliferation of CD4⁺ lymphocytes and of various other cell types via a G² cell cycle arrest. Moreover, Vpr induces cell death through the intrinsic pathway of apoptosis, which involves mitochondrial membrane permeabilization (MMP), the release of cytochrome *c* from mitochondria, and the cytochrome *c*-dependent activation of caspases (2, 3).

A fraction of Vpr transfected into cells can be found in the mitochondrial compartment (2). When added to purified mitochondria, recombinant or synthetic Vpr crosses the outer membrane through the voltage-dependent anion channel. It then interacts with the adenine nucleotide translocator (ANT) in the inner mitochondrial membrane to form a composite ion channel. This channel dissipates the $\Delta\psi_m$ and thus favors MMP and subsequent apoptosis (3). The physical interaction between Vpr and ANT has been determined by coimmunoprecipitation, electrophysiological measurements, and surface plasmon resonance (3). Vpr fails to kill ANT-deficient cells (3), which suggests that the Vpr/ANT interaction is central to the apoptosis-inducing properties of Vpr.

Vpr is mutated in LTNPs

In this issue of the *JCI*, Badley and colleagues (1) report that 80% of LTNPs manifest a point mutation in Vpr

Address correspondence to: Guido Kroemer, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8125, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France.
Phone: 33-1-42-11-60-46;
Fax: 33-1-42-11-60-47; E-mail: kroemer@igr.fr.

Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: long-term nonprogressive/nonprogressor (LTNP); mitochondrial transmembrane potential ($\Delta\psi_m$); viral protein R (Vpr); mitochondrial membrane permeabilization (MMP); adenine nucleotide translocator (ANT).

Figure 1

Impact of the R77Q mutation of Vpr on the conformation of Vpr and the interaction between Vpr and ANT. (a) Representation of wild-type (R77) Vpr and R77Q Vpr. Three amphipathic helices (shown in red and yellow) are linked by turns (green) and flexible loops (gray). The mitochondriotoxic domain of Vpr has been marked in yellow. Only the side chain of amino acid 77 is shown. (b) View of the arginine residues (R73, R77, R80) within the mitochondriotoxic domain of Vpr (yellow) and the aromatic residues of ANT (F109, W111, Y113 and/or F114) involved in cation- π interactions, as calculated by molecular modeling (10). The inner mitochondrial membrane (dark blue) is indicated to facilitate the topological orientation of the third loop (residues 104–116) of ANT. C, carboxy terminus; N, amino terminus; L134 and R72 are amino residues of ANT.

leading to the exchange of arginine 77 with a glutamine residue. This mutation (R77Q) is far less frequent (33%) among patients with progressive disease. Badley and coauthors' analysis confirms previous studies (4) and supports the idea that Vpr may serve as a mediator of CD4⁺ T cell depletion in HIV infection. In T cell infections utilizing vesicular stomatitis virus G protein–pseudotyped HIV-1 particles, the R77Q mutation had no impact on cell cycle arrest or viral replication, yet it led to a significant reduction in apoptosis (1). Compared to the wild-type Vpr peptide, a synthetic Vpr peptide carrying the R77Q mutation induced much less apoptosis, $\Delta\psi_m$ dissipation, cytochrome *c* release, and caspase-3 activation (1). This result has been demonstrated in vitro, when Vpr-derived peptides were added to human T lymphoma cells, and in vivo,

when such peptides were injected into mice in which the depletion of CD4⁺ and CD8⁺ T cells was being monitored (1). Based on these findings, Badley and coauthors (1) propose that the R77Q mutation (and the subsequent reduction in Vpr-mediated apoptosis) might explain the LTNP phenotype.

How the Vpr mutation attenuates Vpr function

How is it possible that the R77Q mutation reduces Vpr-mediated apoptosis induction and HIV-1 virulence, even though computer-based calculations do not predict any major effect of this single amino acid substitution on the overall folding of the α -helical structure (5) of Vpr (Figure 1a)? The answer to this enigma may reside in the mechanism through which Vpr interacts with ANT. Indeed, the minimum unit of Vpr capable of inducing

MMP in vitro in isolated mitochondria is a dodecapeptide (aa 72–83) located within the C-terminal α -helix (3). This mitochondriotoxic domain contains three arginine (R) residues (R73, R77, and R80), which asymmetrically distribute to just one side of the α -helix and participate in the physical interaction with one particular moiety of the six-transmembrane domain ANT, namely the first loop (amino acids 104–116) exposed to the mitochondrial intermembrane space. These positively charged R residues (e.g., R77, but also R73 or R80) within Vpr are likely to be involved in cation- π interactions with F109, W111, Y113 and/or F114 within ANT (Figure 1b). This type of noncovalent binding, which is as least as strong as a hydrogen bond, is increasingly considered for drug design and has been shown to be instrumental for antigen recognition by immune receptors, detection of DNA damage by repair enzymes, and ligand-elicited receptor signaling (6). Mutations of R77, as described by Badley and colleagues (1), may be expected to strongly reduce the affinity of Vpr for ANT. This would explain the reduced mitochondriotoxic and proapoptotic potential of Vpr R77Q.

Based on these findings, several tantalizing possibilities arise. It appears possible that R77Q could act as a dominant-negative Vpr mutant, based on the previous finding that R73-mutated Vpr reverses the wild-type Vpr-mediated block in host cell proliferation, presumably through the N-terminus-mediated oligomerization with wild-type Vpr (7). Such dominant-negative Vpr inhibitors, as well as synthetic blockers of the Vpr/ANT interaction, may be expected to have a positive impact on the prognosis of HIV-1 infection, provided that Vpr and the Vpr/ANT interaction are truly important for AIDS pathogenesis. Indeed, HIV protease inhibitors have already been shown to suppress the MMP-inducing effects of two ANT ligands, Vpr and atractyloside, as assessed using isolated mitochondria (8). This could explain why HIV-1 protease inhibitors can inhibit HIV-1-induced apoptosis, independently of their anti-retroviral effect.

It is also important to note that the proapoptotic Vpr protein is not the only viral mitochondrion-targeted protein to be identified as a virulence factor (9). It will be interesting to learn which other viruses produce similar mitochondrion-targeted, apoptosis-regulatory, disease-relevant proteins, all of which could constitute promising pharmacological targets.

Acknowledgments

Our work is supported by grants from the Centre National de la Recherche Scientifique, the Agence Nationale pour la Recherche sur le SIDA, the Association pour la Recherche sur le Cancer, the Fondation pour la Re-

cherche Médicale, the European Commission (QLG1-CT-1999-00739), the Ligue Nationale contre le Cancer, and the Ministry of Science. The authors thank Aurélien Deniaud for assistance in molecular modeling.

1. Lum, J.J., et al. 2003. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. *J. Clin. Invest.* **111**:1547–1554. doi:10.1172/JCI200316233.
2. Jacotot, E., et al. 2000. The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore. *J. Exp. Med.* **191**:33–46.
3. Jacotot, E., et al. 2001. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2. *J. Exp. Med.* **193**:509–520.
4. Zhang, L., Huang, Y., Yuan, H., Tuttleton, S., and Ho, D. 1997. Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of

human immunodeficiency virus type 1 infection. *Virology*. **228**:340–349.

5. Morellet, N., Bouaziz, S., Petitjean, P., and Roques, B. 2003. NMR structure of the HIV-1 regulatory protein VPR. *J. Mol. Biol.* **327**:215–227.
6. Zacharias, N., and Dougherty, D. 2002. Cation- π interactions in ligand recognition and catalysis. *Trends Pharmacol. Sci.* **23**:281–287.
7. Sawaya, B., et al. 2000. Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73. *J. Virol.* **74**:4877–4881.
8. Phenix, B., Lum, J., Nie, Z., Sanchez-Dardon, J., and Badley, A. 2001. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. *Blood*. **98**:1078–1085.
9. Castedo, M., Perfettini, J.L., and Kroemer, G. 2002. Mitochondrial apoptosis and the peripheral benzodiazepine receptor: a novel target for viral and pharmacological manipulation. *J. Exp. Med.* **196**:1121–1125.
10. Sali, A., and Blundell, T. 1993. Comparative protein modelling by satisfaction of spatial restraints. *J. Mol. Biol.* **234**:779–815.

See the related articles beginning on pages 1463 and 1497.

A matter of life and death: cardiac myocyte apoptosis and regeneration

Bernardo Nadal-Ginard, Jan Kajstura, Piero Anversa, and Annarosa Leri

Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla, New York, USA

J. Clin. Invest. **111**:1457–1459 (2003). doi:10.1172/JCI200318611.

Of late, life has become more complicated in cardiovascular biology. Life was simpler when the prevalent dogma stating that the heart is a terminally differentiated organ without regenerative capacity remained unchallenged (1). This static view of the myocardium implied that both myocyte death and myocyte replication played no meaningful role in cardiac homeostasis and could be safely ignored. In the absence of myocyte renewal, cell death by apoptosis or necrosis had to be extremely low or non-existent to explain the preservation of the cardiac mass throughout the lifespan of the individual. Even very low

rates of myocyte death would have resulted in the complete disappearance of the myocardium in a few decades. Thus, it is not surprising that the existence of myocyte apoptosis remained controversial during the past decade (2). Recent findings indicating the presence in the adult myocardium of a cell population with the behavior and potential of cardiac stem cells has challenged the status quo, provided an explanation for the existence of a subpopulation of immature cycling myocytes and embraced myocyte death and myocyte renewal as the two sides of the proverbial coin of cardiac homeostasis (3). This myocyte renewal depends on the differentiation of primitive cells into immature myocytes that might divide two to four times before becoming terminally differentiated and permanently withdrawn from the cell cycle. There is no evidence that already mature cardiomyocytes can de-differentiate, re-enter the cell cycle, and proliferate. In

this new light, the presence, regulation, and physiological consequences of myocyte apoptosis have gained new significance. Two papers in this issue of the *JCI* highlight the effect of this type of myocyte death in cardiac performance and provide new insights on the role of myocyte death and renewal in cardiovascular physiology (4, 5).

Diffuse cell death leads to dilated cardiomyopathy

Although it is well accepted that myocyte death is a determining factor of ventricular dysfunction and end-stage failure (6), whether diffuse myocyte apoptosis can, by itself, cause cardiac failure has remained controversial. The pattern of cell death within the myocardium has distinct consequences on cardiac function. Moderate scattered myocyte death has a greater negative effect on ventricular hemodynamics than equivalent segmental myocyte loss (7). It takes the destruction of 40–50% of left ventricular myocytes after coronary artery occlusion to produce cardiac failure (8), while a 10–20% myocyte dropout dispersed throughout produces the same result (7). The two animal models of myocyte apoptosis published in this issue of the *JCI* (4, 5) provide conclusive proof that myocyte dropout by itself can cause cardiac failure. In these studies, appearance of dilated cardiomyopathy is mediated by diffuse myocyte apoptosis across the

Address correspondence to: Bernardo Nadal-Ginard, Cardiovascular Research Institute, Department of Medicine, New York Medical College, Valhalla, New York 10595, USA. Phone: (914) 594-4755; Fax: (914) 594-4406; E-mail: b_nadal-ginard@nymc.edu.

Conflict of interest: The authors have declared that no conflict of interest exists.

Nonstandard abbreviations used: mammalian sterile 2-like kinase 1 (Mst1).